Opus Genetics will present the complete clinical dataset from Cohort 1 of its Phase 1/2 trial of OPGx-BEST1 gene therapy at the Retina in Rio conference on October 14, 2026. The presentation is part of a series of disclosures at major ophthalmology meetings and will include additional analyses of visual function in patients with BEST1-related retinopathy.
The company announced topline data from Cohort 1 in early September 2026. The medical community and investors are watching for more detailed information on the therapy’s safety and efficacy.